bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 13 2025
0mins
Source: Newsfilter
Investment Announcement: bioAffinity Technologies has entered into securities purchase agreements for the sale of 990 shares of Series B Convertible Preferred Stock and warrants, aiming to raise approximately $1.2 million for working capital and corporate purposes.
CyPath® Lung Test: The company’s noninvasive test, CyPath® Lung, demonstrates high sensitivity and accuracy in detecting early-stage lung cancer, utilizing advanced flow cytometry and AI technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
